GLOBAL CARE CAPITAL INC.

(FORMERLY RESINCO CAPITAL PARTNERS INC.)

MANAGEMENT DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS

FOR THE SIX MONTHS ENDED

JUNE 30, 2020 AND 2019

INTRODUCTION

The following management discussion and analysis – quarterly highlights ("MD&A – Quarterly Highlights") of the results of operations and financial condition of Global Care Capital Inc. (formerly Resinco Capital Partners Inc.) ("Global" or the "Company") for the six months ended June 30, 2020 and up to the date of this MD&A – Quarterly Highlights, has been prepared to provide material updates to the business operations, financial condition, liquidity and capital resources of the Company since its last management discussion and analysis for the year ended December 31, 2019 (the "Annual MD&A")

This MD&A – Quarterly Highlights should be read in conjunction with the Annual MD&A and the audited financial statements for the year ended December 31, 2019, together with the notes thereto, and the accompanying unaudited condensed interim financial statements and related notes thereto for the six months ended June 30, 2020 (the "Financial Report").

All financial information in this MD&A – Quarterly Highlights is derived from the Company's financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") and all dollar amounts are expressed in Canadian dollars unless otherwise indicated.

The effective date of this MD&A – Quarterly Highlights is August 31, 2020.

DESCRIPTION OF BUSINESS

Global was incorporated under the laws of British Columbia on May 25, 2004. The Company's shares are listed for trading on the Canadian Securities Exchange ("CSE") under the ticker symbol "RIN", the Frankfurt Stock Exchange under the symbol L6V1.F and on the United States OTC stock market's OTC Pink, under the symbol RSCZF. The registered office of the Company is Suite 810 – 789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

Global is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The impact on the Company is not currently determinable but management continues to monitor the situation.

OPERATIONAL HIGHLIGHTS

Investment Acquisitions

ViraxClear Rapid Test Corp.

On April 17, 2020, the Company acquired all of the issued and outstanding shares of ViraxClear Rapid Test Corp. d/b/a ViraxClear ("ViraxClear").. ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company's main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test and ViraxCare PPE. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies. ViraxCare is aimed at minimizing at-work risks by supplying PPE for employees and innovative products and devices which monitor potential viral outbreaks.

High Standard Health Care Ltd.

On June 5, 2020, the Company acquired 70% of High Standard Health Care Ltd. ("HSHC") in exchange for 27,000,000 of the Company's common shares. High Standard Health Care is a leading global PPE provider assisting front line workers during the global pandemic. To date the company has procured respiratory masks, gowns, hand sanitizer, infrared thermometers, and face shields. To date High Standard Health Care customers, include hospitals, schools, municipalities, long-term care facilities, fire departments and police departments.

OPERATIONAL HIGHLIGHTS (continued)

Investment Acquisitions (continued)

Reformation Pharmaceuticals Corp.

On June 30, 2020, the Company completed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp. (the "Purchaser") pursuant to the share purchase agreement between Global Care and the Purchaser signed on June 24, 2020. The Purchaser acquired all the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser.

Share consolidation

On March 13, 2020, the Company completed a share consolidation of its share capital on a 25:1 basis. As a result of the share consolidation, the 122,331,000 common shares issued and outstanding were consolidated to 4,893,235 common shares. All common shares and per share amounts have been restated to give effect to the share consolidation.

Resignations and appointment

On January 13, 2020, the Company announced the resignations of Mr. Theo. van der Linde as Chief Financial Officer and Mr. Eugene Beukman as Corporate Secretary. The Company would like to thank Messrs. van der Linde and Beukman for their contributions to the Company and wishes them well in their future endeavours.

On April 15, 2020, the Company announced the appointment of Mr. James Henning as Chief Financial Officer.

James Henning is a Chartered Professional Accountant and the Founder and President of Corpfinance Advisors Inc. since 1984. Mr. Henning has solid expertise and practical experience in valuating businesses in a broad range of industries. He has assisted companies in financing, public offerings, and restructuring. Areas of expertise include manufacturing, telecommunications, software, biomedical, oil & gas services and renewable energy industries. Mr. Henning has served as a Chief Financial Officer and Director for a number of TSX Venture Exchange and Canadian Securities Exchange listed companies over the past several years.

Company name and symbol changes

On April 15, 2020, the Company changed its name from Resinco Capital Partners Inc. to Global Care Capital Inc. Effective April 17, 2020, the Company's common shares began trading under the new name and the ticker symbol "HLTH" on the Canadian Securities Exchange.

The Company engaged in due diligence and research procedures in search of new, early stage investment opportunities in the healthcare sector to diversify and strengthen its existing portfolio. The name and ticker symbol change reflect an initiative to align the Company brand with this new strategic focus.

KEY INVESTMENT PORTFOLIO DESCRIPTION

ViraxClear Rapid Test Corp.

Pursuant to the terms of the Share Purchase Agreement with ViraxClear, Global Care Capital issued 24,000,000 common shares of the Company (each a "Consideration Share") to vendors in return for a 100% interest in ViraxClear. At closing, the ViraxClear option holders exchanged their outstanding ViraxClear options (the "ViraxClear Options") for replacement Global Care Capital options (each a "Global Care Capital Option"). Each ViraxClear Option was exchanged for a Global Care Capital Option on a 1:1 basis for an aggregate of 2,900,000 Global Care Capital Options. Of the aggregate number of Global Care Capital Options to be issued, 2,400,000 Global Care Capital Options have an exercise price of $0.50 per Global Care Capital common share until April 15, 2022; and 500,000 Global Care Capital Options have an exercise price of $0.20 per Global Care Capital common share until April 15, 2022.

As a major investment into the healthcare sector, ViraxClear presents a tremendous opportunity. The novel coronavirus has become a worldwide pandemic that requires serious intervention for countries to return to status quo. The Company is not making

KEY INVESTMENT PORTFOLIO DESCRIPTION (continued)

ViraxClear Rapid Test Corp. (continued)

any express or implied claims that it has the ability to treat the COVID-19 virus at this time. ViraxClear is a start-up company in the newly created COVID-19 antibody test market and has commenced sales and distribution of its test kits in Mexico.

As a distributor, ViraxClear's focus on commercialization targets the marketing and distribution portion of the value chain. ViraxClear's manufacturing partner, Shanghai Liangrun Biomedicine Technology Co., Ltd., has production capacity of one million test kits per week at their factory in Shanghai, China.

On April 20, 2020, ViraxClear, obtained Emergency Use Authorization (EUA) by the Food and Drug Administration ("FDA") for the COVID-19 test kits it distributes and markets. ViraxClear's tests can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA). ViraxClear's COVID-19 test kit also has CE marking allowing sales to the European Community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration.

On May 5, 2020, ViraxClear finalized supply contracts with Shenzhen Qianhai Huolilang Technology Co., Ltd. ("Qianhai") for the supply of KN95 Masks manufactured by Promask Electronic Medical Device (Guangzhou) Manufacturing Co., Ltd. globally.

On May 13, 2020, ViraxClear signed a letter of intent for the distribution of its COVID-19 Rapid Antibody Test Kits (the "Test Kits") for Morocco.

On May 20, 2020, ViraxClear finalized a Letter Of Intent with Phyto Pharma Ltd, for the supply of 5,000 FDA Registered and CE marked infrared thermometer units for sale in North America, with a Purchase Order signed for the value of US$125,000 for the 5,000 units.

On June 10, 2020, the Company announced that ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd., ("SBD") has now launched its Employee Protection Equipment ("EPE") kit, which will help business owners protect their employees from the transmission of Virax infections, such as COVID-19. ViraxClear will distribute the EPE kits through its newly launched sales platform, ViraxCare, www.viraxcare.com.

On June 25, 2020, the Company announced that ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd., received its approval certificate from the Philippines Food and Drug Administration ("PFDA") for the distribution of COVID-19 Rapid Antibody Test Kits ("Test Kits") for the Philippines market with a contract valued at up to $7,500,000 in gross sales for the distribution of up to 1,000,000 Test Kits for the Philippines.

Following PFDA approval, Philippines medical device distribution company Novarad Asia Pacific Company has become ViraxClear's exclusive distribution partner for the Philippines for ViraxClear Test Kits. The full contract is worth up to $7,500,000, over a 1 year period.

The PFDA requires test kits to be on their approved list before being allowed through customs for sale in the country. ViraxClear tests have been approved in collaboration with Hangzhou Clongene Biotech Ltd., the ViraxClear manufacturing partner for the Philippines region.

On July 7, 2020, the Company announced that its portfolio company, ViraxClear, through its joint venture, SBD has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile ("ISP") for the distribution of COVID-19 Rapid Antibody Test Kits supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co. Ltd, and Vazyme Biotech Co., Ltd ("Innovita", "Vazyme"), for the Chilean market. ViraxClear has signed a non-binding Letter Of Intent ("LOI") with Biosonda Biotecnologia ("Biosonda") for the distribution of up to 3,000,000 Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.

ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.

KEY INVESTMENT PORTFOLIO DESCRIPTION (continued)

ViraxClear Rapid Test Corp. (continued)

The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.

On July 7, 2020, the Company announced that ViraxClear is the PPE supplier for The Big Issue Charity ("The Big Issue") supplying EPE kit to The Big Issue through its ViraxCare platform, www.viraxcare.com.

The Big Issue is one of the UK's leading social businesses and exists to offer homeless people, or individuals at risk of homelessness, the opportunity to earn a legitimate income, thereby helping them to reintegrate into mainstream society. It is the world's most widely circulated street newspaper, published in four continents. From an award-winning magazine offering employment opportunities to people in poverty, a multimillion-pound social investment business supporting enterprise to drive social change, to a charity foundation supporting vendors to rebuild their own pathways to a better future and a shop curating social enterprise products. For 29 years The Big Issue Group has strived to dismantle poverty through creating opportunity, in the process becoming one of the most recognised and trusted brands in the UK.

On August 10, 2020, the Company announced that ViraxClear, through its joint venture with Shanghai Biotechnology Devices Ltd. has on August 3rd, 2020, received confirmation of its United States Food and Drug Administration Facility Registration and Device Listing.

CannBioRx Life Sciences Corp. (formerly Katexco Pharmaceuticals)

Katexco was a pre-clinical pharmaceutical cannabis company and was developing innovative, orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco was led by a world class management team with a proven track record and the research is grounded in more than 20 years of academic and industrial research with primary operations at the Stanford University in California.

Katexco, 180 Therapeutics and CannBioRex amalgamated into an entity called CannBioRx Life Sciences Corp ("CannBioRx"). CannBioRx signed a definitive business combination agreement with KBL Merger Corp. IV (NASDAQ:KBLM) ("KBLM"), KBLM is a blank check company that completed its IPO in June 2017, raising $115 million with the goal of identifying and acquiring a company with strong value proposition in the U.S. healthcare or health-care related wellness industry.

CannBioRx has three synergistic programs that operate at the intersection of the biotech and cannabis industries:

- A clinical-stage program focused on the discovery and development of novel therapies to treat fibrosis. This fully enrolled Phase 2b program expects results in Dupuytren's disease during the fourth quarter of 2020.
- A preclinical cannabinoid program focused on the development and commercialization of unique pharmaceutical-grade cannabinoids for arthritis, pain, diabetes and obesity.
- A preclinical program developing innovative, orally available therapies harnessing the brain's nicotinic receptors to treat inflammatory diseases, such as ulcerative colitis, gout and multiple sclerosis.

ReFormation

ReFormation Pharmaceuticals Corp is a Medical Marijuana Pharmaceutical company headquartered in Toronto, Ontario with its Research and Development team at the University of Oxford in London, UK. The company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in class therapeutic. ReFormation has identified a molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. ReFormation's research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and CSO, Professor Jagdeep Nanchahal, of the University of Oxford. ReFormation entered into a letter agreement with 180 Therapeutics LP ("180 Therapeutics") (the "Agreement") pursuant to which 180 Therapeutics will provide ReFormation the right of first negotiation in the event 180 Therapeutics completes its currently contemplated exclusive

KEY INVESTMENT PORTFOLIO DESCRIPTION (continued)

ReFormation (continued)

intellectual property agreement with the University of Oxford (the "Program"). Under the terms of the Agreement, 180 Therapeutics will negotiate exclusively under the right of first negotiation with ReFormation (the "ROFN") regarding a strategic transaction that would result in the acquisition of the Program or provide for an exclusive licensing, partnering or collaboration transaction between ReFormation and 180 Therapeutics. In consideration for the ROFN, ReFormation will pay US$900,000 with a further US$300,000 in tranches over the following 12 months. ReFormation has the option to extend the ROFN with 180 Therapeutics for an additional cash consideration of US$1,800,000 payable in two equal tranches.

On June 29, 2020, the Company entered into a share purchase agreement (the "Agreement") for the sale of all of the issued and outstanding common shares of its wholly-owned subsidiary, ReFormation Pharmaceuticals Corp. (the "ReFormation Shares"), to an arm-length purchaser, 360 Life Sciences Corp. (the "Purchaser") of Delaware, United States. Under the terms of the Agreement, the Purchaser will acquire the ReFormation Shares in exchange for 800,000 common shares in the capital of the Purchaser.

On August 4, 2020 the Company announced that it has closed the sale of all of the issued and outstanding shares of ReFormation to 360 Life Sciences Corp. pursuant to the share purchase agreement between Global Care and the Purchaser The Purchaser acquired all of the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser. No finders fees was paid in connection with the purchase deal.

Global Gaming Technologies Corp.

Global Gaming Technologies Corp. is a gaming industry holding company that provides investment exposure to digital interactive entertainment in emerging technologies, such as Augmented Reality, Virtual Reality, and Artificial Intelligence, in addition to eSports and traditional game platforms, such as mobile and console. It is focused on gamifying content using visual cinematics across all platforms. The Company's strategy is to publish games and content that are immersive in storytelling, bold in design, and technologically innovative. The Company is managed by game and film industry pioneers. It is headquartered in Toronto, Canada with its primary game studio in Los Angeles, California. GGAM is listed on the Canadian Securities Exchange ("CSE") and its common shares trade under the ticker symbol "GGAM.U". On December 31, 2019, the Company impaired its investment in Global to $Nil due to the fact that Global needs to raise significant money to settle its debt and the uncertainty of its ability to raise these funds in a timely manner, resulting in $392,544 of impairment expense.

Metaverse Capital Corp.

On June 20, 2019, the Company received 5,058,583 common shares of Metaverse Capital Corp. valued at $101,172 as a stock dividend. On December 31, 2019, the Company wrote down its investment to $Nil due to the fact that the Metaverse is delisted, resulting in $101,172 of impairment expense.

High Standard Health Care Ltd.

On June 5, 2020, the Company acquired 70% of the issued and outstanding common shares of High Standard Health Care Ltd. ("HSHC"), pursuant to a Share Purchase Agreement dated May 29, 2020 (the "Transaction"). The Company issued 27,000,000 common shares to HSHC shareholders with a fair market value of $6,885,000 and 3,000,000 common share purchase warrants in consideration for the Transaction. Each warrant permits the holder to acquire one common share of the Company at a price of $0.375 until June 5, 2021.

In addition, the Company will pay $5,000,000 cash or issue common shares ("Performance Shares") at the discretion of the Company at the time a Milestone Target is met for every $14,300,000 in gross revenue generated by HSHC effective upon HSHC reaching $21,430,000 in revenue ("Milestone Targets") up to a maximum of $286,000,000 in gross revenue or 20 Milestone Targets on or before May 31, 2025 for total value of up to $100,000,000 if all Milestone Targets are achieved. The Company may issue up to 26,500,000 Payment Shares in satisfaction of met Milestone Targets.

On June 5, 2020, the Company granted 1,000,000 share options to an officer of HSHC exercisable at a price of $0.285

per share until June 5, 2025 as consideration for the acquisition of HSHC.

High Standard Health Care specializes in procuring personal protective equipment ("**PPE**") including but not limited to respiratory masks, hand sanitizer, gowns, infrared thermometers and face shields and has been active in procurement during COVID-19 for hospitals, municipalities, schools, long-term care facilities, fire departments and police departments. Recently High Standard Health Care was engaged to procure 2 million respiratory masks for a hospital in upstate New York due to the significant shortage and difficulty of securing PPE during the pandemic. This order was delivered late April 2020 and re-orders continue. High Standard Health Care works with trusted supply partners globally that provide favorable terms and real time shipments during a time where PPE is scarce and difficult to procure. During the first two months of operations High Standard Health Care generated approximately $4 million in purchase orders with a gross margin of approximately 40%.

On June 12, 2020, the Company announced that HSHC received $350,000 for a purchase order of level two medical gowns from a New York hospital.

On July 6, 2020, HSHC entered into an Approved Vendor Contract (the "Contract") to become an Approved Vendor for Nevada based long term care facility, Alta Skilled Nursing and Rehab Centre ("Alta"). HSHC will have the right of first offer for agreed upon PPE purchased by Alta.

On July 8, 2020, the Company announced that its portfolio company HSHC has, pursuant to entering into the previously announced Contract with Alta on July 6th, 2020, become an Approved Vendor for Alta.

EQUITY TRANSACTIONS

On January 15, 2019, the Company issued 1,160,000 common shares with a fair value of $7,105,000 pursuant to the acquisition of ReFormation. The Company issued 81,200 common finders' fee shares with a fair value of $497,350, which was measured on the basis of the Company's observable market price.

The Company also issued 6,800 common shares pursuant to a warrant exercise for gross proceeds of $18,250. The Company re-allocated $88,405 from share-based payments reserve to share capital.

On April 9, 2020, the Company completed a non-brokered private placement of 25,000,000 units (the "Units" and each individually, a "Unit") for gross proceeds of $2,450,000 and to settle outstanding debt of $50,000 (the "Offering"). Each Unit is comprised of one common share of the Company at a price of $0.10 per common share and one-half of one common share purchase warrant at a price of $0.20. Each whole warrant will be exercisable for a period of 24 months from the closing of the Offering. In connection with the private placement, the Company incurred $194,425 in transaction costs and issued 1,944,250 finder warrants with a fair value of $1,274,545 to arm's length individuals. Each finder warrant will be exercisable for a period of 24 months at a price of $0.10.

On April 17, 2020 the Company issued 24,000,000 of the Company's common shares with a fair value of $16,920,000 to acquire 100% interest in ViraxClear.

On April 17, the Company paid transaction cost of 2,400,000 common shares with a fair value of $1,692,000 to various arm's-length parties as payment of finder's fees in connection with the acquisition of ViraxClear.

On June 5, 2020, the Company issued 27,000,000 common shares, with a fair value of $6,885,000 to acquire 70% of HSHC.

During the six month period ended June 30, 2020, the Company issued 250,000 common shares for gross proceeds of $125,000 pursuant to stock options exercised.

TRENDS AND INVESTMENT STRATEGY

Global is focused on early-stage investment opportunities in private and public companies. The Company recognizes two enterprise value enhancers; (1) the transition from private to public assets, and; (2) investing in assets which have been over-looked and have not realized their latent potential.

TRENDS AND INVESTMENT STRATEGY (continued)

Engagement of this strategy has resulted in increases in the value of the Company's portfolio historically, however the depressed state of the junior market sector has affected all publicly traded entities over the last several years. All forms of financing continue to be very constrained for early stage companies and this has resulted in the quantity of financings to be severely reduced and arduous to complete successfully.

Due to the depressed state on the junior markets, the Company reviewed potential opportunities in Block Chain and Technology sector and is now focused on potential investments in the Cannabis Pharmaceutical Sector. In particular, the Company is reviewing early stage investment opportunities in previously underdeveloped life and sciences and biotech companies with a specific focus on Cannabis Pharma.

The Company evaluates its portfolio on a regular basis and is actively reviewing new opportunities for investment.

INVESTMENTS SUMMARY

	June 30, 2020		December 31, 2019	
	Cost	**Fair value**	**Cost**	**Fair value**
Public Company Investments	$ 2,446,518	$ 11,862	$ 7,714,020	$ 23,850
Private Company Investments	36,407,000	24,281,001	12,602,000	462,001
Total	$ 38,853,518	$ 24,292,863	$ 20,316,020	$ 485,851

As at June 30, 2020 the Company held public company investments with a fair value of $11,862 compared to $23,850 at December 31, 2019, a decrease of 50%. This is mainly due to the sale of public company investments as well as due to the $10,000 increase in fair value of the 100,000 shares the Company held in Central Iron Ore Limited at June 30, 2020. During the six months ended June 30, 2020, the Company sold 143,447 shares of Bearing Lithium Corp. for gross proceeds of $14,661, and 23,750 shares of Digihost Tech Inc. for gross proceeds of $14,920.

As at June 30, 2020, the Company held private company investments with a fair value of $24,281,001, compared to $462,001 at December 31, 2019. This increase is due to the Company's acquisition of High Standard and ViraxClear.

RESULTS FROM OPERATIONS

Six Months Ended June 30, 2020

The Company's net realized gain on disposal of investments for the six months ended June 30, 2020 was $8,604, compared to a net realized loss on disposal of investments of $5,647 for the six months ended June 30, 2019. The net realized gain on disposal of investments for the six months ended June 30, 2019 is due to the sale of certain public company investments as described above. The net realized loss on disposal of investments for the six months ended June 30, 2019 is due to the sale of 25,000 common shares of Lithium Americas Corp. ("LAC") for gross proceeds of $102,899, 200,000 common shares of Bearing Lithium Corp. ("BRZ") for gross proceeds of $48,000 and 9,984 shares of Lions Bay Mining Corp. ("LBM") for gross proceeds of $1,218.

In addition, the Company recorded a net change in unrealized gain on investments of $22,989 for the six months ended June 30, 2020, compared to a net change in unrealized loss on investments for the six months ended June 30, 2019 of $390,707. The change in unrealized gain is largely due to fluctuations in the valuation of the Company's investments.

The Company's expenses for the six months ended June 30, 2020 were $7,386,874 compared to expenses of $1,616,950, for the six months ended June 30, 2019. Overall, the Company had increased in investing and financing activity during Q2 2020 in its efforts to raise capital and purchase investment vehicles during economic downturn.

The key differences in expenses between the six months ended June 30, 2020 and 2019 were as follows:

- Consulting fees increased by $57,320 due to increase in activities during the period ended June 30, 2020. The company relies on the expertise of consultants to help them achieve their goals on all facets of business and these consultants bring a wide range of expertise and connections to the Company. Consultants include management, advisors, marketing and other support roles.

RESULTS FROM OPERATIONS (continued)

- Corporate development decreased by $666,322 due to eliminating expenditures on Media, Public Relations and other forms of communication to preserve capital.
- Office and miscellaneous decreased by $35,701 due to eliminating expenditures on website hosting and administration to preserve capital.
- Professional fees increased by $20,321 due to increase in acquisitions during the period resulting in more legal fees related to due diligence work.
- The Company incurred share-based compensation expense of $1,783,696 during the period ended June 30, 2020 to compensate officers, consultants and directors for completion of investment acquisitions and private placement.
- Transaction costs increased by $3,803,500. For the acquisitions of ViraxClear and HSHC in 2020, the Company retained cash by issuing options and warrants as a part of the consideration amounts in the acquisitions. The 2019 transaction costs were related to finder's fees paid in connection with acquisition of ReFormation.
- The Company incurred Advertising and Promotion costs of $831,662 during the period ended June 30, 2020 to increase visibility of the company during the time when the Company is expanding through acquisitions and increasing capital.

During the three-month period ended June 30, 2020, the Company incurred a net loss of $ 7,292,393 compared to a loss of $712,416 in the comparative period. A significant potion of expenditure relates to professional fees, share-based compensation, transaction costs and advertising costs, which were incurred to acquire investments, raise funding and create awareness within the market for the Company's rebranding. In addition, the Company decreased corporate development expenses to $nil (2019 – $331,111) to limit cash outflow.

SUMMARY OF QUARTERLY RESULTS

	Three months ended			
	June 30, 2020	**March 31, 2020**	**December 31, 2019**	**September 30, 2019**
Net revenues (losses)	$440	$35,665	494,049	$(20,980)
Net income (loss) for the period	$(7,292,833)	$(58,376)	(10,874,242)	(136,333)
Earnings (loss) per share – basic and diluted	(0.13)	(0.01)	(2.24)	(0.03)

	Three months ended			
	June 30, 2019	**March 31, 2019**	**December 31, 2018**	**September 30, 2018**
Net revenues (losses)	$(155,812)	$(234,900)	$(2,056,964)	$(1,473,744)
Net income (loss) for the period	$(712,416)	$(1,295,256)	(3,576,456)	(1,650,608)
Earnings (loss) per share – basic and diluted	(0.25)	(0.28)	(1.25)	(1.00)

The quarterly financial information for 2020, 2019 and 2018 fiscal periods are presented in accordance with IFRS.

The Company has been negatively affected by poor stock market performance, volatile commodity prices and weakened global economic performance. Due to an investment portfolio which is weighted in early-stage companies, quarter-to-quarter performance is affected by volatility in the stock markets. The amount and timing of expenses and availability of capital resources vary substantially quarter to quarter, depending on the level of investment activities being undertaken at the time.

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2020, the Company had cash of $670,095 and working capital of $26,539,905, compared to $14,498 and of $1,600,357, respectively as at December 31, 2019. Since the Company's inception, operations have been financed through the issuance of equity securities and the sale of the Company's investments.

LIQUIDITY AND CAPITAL RESOURCES (continued)

The Company began the period with cash of $14,498. In the six months ended June 30, 2020, the Company used net cash of $1,364,559 on operating activities, used $410,419 on investing activities and received $2,430,575 from financing activities, to end June 30, 2020 with $670,095 in cash.

During the six months ended June 30, 2020, the Company limited cash outflow due to operating activities through share-based compensation in the amount of $1,753,892. As well, to complete acquisitions, the company incurred transaction costs through the issuance of options and warrants in the amount of $4,300,850.

During the six months ended June 30, 2020, the Company sold 143,447 shares of Bearing Lithium Corp. for gross proceeds of $14,661, and 23,750 shares of Digihost Tech Inc. for gross proceeds of $14,920. As part of the transaction to acquire the shares of ViraxClear, the Company has agreed to provide a minimum cash amount of $1,000,000 to ViraxClear. As at June 30, 2020, the Company has loaned $440,000 to ViraxClear. The funding is used towards inventory management, working capital, and product development.

During the six months ended June 30, 2020, the Company issued 250,000 common shares for gross proceeds of $125,000 pursuant to stock options exercised.
On January 17, 2020, the Company entered into a loan agreement in the amount of $50,000 with a company jointly controlled by the former corporate secretary and CFO. The loan is due on demand and interest will accrue on the principal amount at the rate of 8% per annum. As at June 30, 2020, the loan has been settled through issuance of shares, as part of the private placement completed on April 9, 2020.

On April 9, 2020, the Company received $2,255,575 in proceeds net of finders fee of $194,425 for the completion of the private placement issuance of 25,000,000 common shares of the Company.

As at June 30, 2020, the Company had investments valued at $24,281,001. Funding for the Company's operations is generated from the sale of investments in its portfolio and private placements. Most of the value of the portfolio of investments is comprised of three private companies. Subsequent to June 30, 2020, the Company closed the sale of 100% of shares of its portfolio investment, Reformation, to 360 Life Sciences Corp. in exchange for 800,000 common shares of the Purchaser. While the Company has been successful in securing financing, there can be no assurance that it will be able to do so in the future.

CASH FLOWS – OPERATING ACTIVITES

Net cash used in operating activities during the six months ended June 30, 2020 was $1,332,108 (2019-$1,113,958) which mainly consisted of cash spent for general working capital, brand awareness campaigns, consulting and professional fees for investment opportunities.

CASH FLOWS – FINANCING ACTIVITES

Total net cash generated during the period ended was $2,430,575 (2019 - $18,250), which is from proceeds from a settled loan, proceeds from options exercised and proceeds from private placement.

CASH FLOWS – INVESTING ACTIVITES

During the six months ended June 30, 2020, the Company sold investments of $29,581 (2019 - $150,103), and realized a gain of $8,604 on the sale of investments. The Company also provided loans in the amount of $440,000 to its portfolio investment company, ViraxClear, during the six months ended June 30, 2020.

CONTRACTUAL OBLIGATIONS

As at June 30, 2020, the Company is obligated to provide a minimum cash amount of $1,000,000 to ViraxClear. As at June 30, 2020, the Company has loaned $440,000 to ViraxClear.

OFF-BALANCE SHEET ARRANGEMENTS

The Corporation was not party to any off-balance sheet arrangements as of June 30, 2020.

RELATED PARTY TRANSACTIONS

The Directors and Executive Officers of the Company are as follows:

Alexander Somjen	Director, Chief Executive Officer & President
James Henning	Chief Financial Officer (appointed April 15, 2020)
Theo van der Linde	Chief Financial Officer (resigned on January 13, 2020)
Eugene Beukman	Corporate Secretary (resigned on January 13, 2020)
Troy Grant	Director
Maciej Lis	Director

The following directors and/or senior officers transacted with the Company in the reporting period. The terms and conditions of

the transactions with key management personnel and their related parties were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to non-key management personnel related entities on an arm's length basis. The aggregate value of transactions relating to key management personnel were as follows:

	June 30, 2020	June 30, 2019
Consulting fees paid to the CEO	$ 101,700	$ 101,700
Consulting fees paid to the CFO	1,575	-
Corporate fees paid to a company controlled by the former corporate secretary	3,125	45,675
Rent, consulting and accounting fees paid to companies controlled by the former CFO	6,850	22,050
Total	$ 113,250	$ 169,425

As at June 30, 2020, there was $279,388 (December 31, 2019 - $132,150) due to current and former officers and management of the Company, and loan receivable of $1,200,780 (December 31, 2019 - $1,200,780) due from ReFormation Pharmaceuticals Corp.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments

The Company's financial instruments consist of cash, receivables, share subscriptions receivable, loan receivable, investments and trade and other payables. The carrying value of receivables, loan receivable, share subscriptions receivable and trade and other payables approximates their fair value due to the short-term nature. Cash is recorded at fair value using Level 1 of the fair value hierarchy. Investments are recorded at fair value using Level 1 to 3 of the fair value hierarchy.

The Company's financial instruments recorded at fair value require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.

Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the market place.

Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

The following table presents the Company's investments, measured at fair value on the statements of financial position and categorized into levels of the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
June 30, 2020	$ 670,095	$ -	$ 24,281,001	$ 24,951,096
December 31, 2019	$ 23,850	$ -	$ 462,001	$ 485,851

The Company holds investments in HSHC, ViraxClear, Pembrook, CannBioRx (formerly Katexco), ReFormation, Metaverse and Vancity Green, all private company investments are considered Level 3. The fair value of investments in Level 3 for Pembrook is determined by referring to the most recent equity financing the investee undertook during the year or by taking a weighted average of the net assets of the private company and the value of its historical share issuance transactions. The fair value of investments for CannBioRx (formerly Katexco) is based on the most recently completed private placement. The fair value for Vancity Green is based on the Company's most recent financings or transactions and an assessment as to whether there have been any adverse changes from the date of acquisition. The fair value for ReFormation is based on an assessment as to whether there have been any changes in the Company's circumstances since the date of acquisition. All changes in fair value of these private company investments are recognized in profit or loss on the statements of loss and comprehensive loss.

The amounts included in profit or loss are comprised entirely of unrealized gains and losses. There were no transfers between levels during the period.

The following table reconciles the Company's Level 3 fair value investments:

Level 3	Six months ended June 30, 2020	Six months ended June 30, 2019
Balance, beginning of period	$ 462,001	$ 4,035,000
Additions	23,805,000	7,602,350
Unrealized (loss)/gain	14,000	-
Balance, end of period	24,281,001	11,637,350

Risk management

The Company is or may be subject to certain risks including interest rate risk, currency risk, credit risk and market risk. Risk management strategies may expose the Company to further gains or losses, but serve to stabilize future cash flows, reduce the volatility of operating results and increase overall financial strength.

Interest rate risk

The Company is exposed to interest rate risk to the extent that its cash balances bear variable rates of interest. The interest rate risks on cash and on the Company's obligations are not considered significant.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

Risk management (continued)

Currency risk

The Company has foreign investments and is therefore subject to currency risk. Management believes these investment and transaction amounts are not significant and there are no material foreign currency commitments. The currency risk is therefore manageable and not significant. The Company does not currently use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.

Credit risk

Credit risk is the risk associated with the inability of a third party to fulfil its payment obligations. The Company is exposed to the risk that third parties that owe money or securities in connection with services provided, or for other purposes, will default on their underlying obligations.

Prior to accepting any service engagement or providing any loan, the Company assesses future recoverability by examining the entities' financial conditions, properties and assets, business development activities and management. The Company manages its exposure to credit risk by reviewing the outstanding balances on an ongoing basis, monitoring the amount attributable to each counterparty, and the length of time taken for amounts to be settled. Where necessary, management takes appropriate action to follow up on those balances considered overdue.

Liquidity risk

Liquidity risk is the risk that the Company will have insufficient cash resources to meet its financial obligations as they become due. The Company's liquidity and operating results may be adversely affected if the Company does not have access to the capital
markets, whether as a result of a downturn in general market conditions or related to matters specific to the Company, or if the value of the Company's investments decline, resulting in lower proceeds and/or losses on disposition. The Company generates cash flows primarily from the disposition of its investments and from its financing activities.

The Company's investments focus on early-stage companies which can at times be relatively illiquid and if the Company decides to dispose of certain securities, it may not be able to do so at favorable prices at that time, or at all. However, the Company has sufficient marketable securities which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions such that, in the absence of overall market disruptions or exceptional circumstances, liquidity risk can be minimized.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The Company's investments are primarily concentrated in early-stage companies, which results in exposure to higher volatility than broader market investments and indexes. The Company's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that changes in market prices result in a proportionate change in the carrying value of the Company's investments. A 10% change in the fair values of the Company's investments at June 30, 2020 would have a $2,429,286 (2019- $48,000) impact on operations.

Concentration risk

The Company is subject to concentration risk due to the nature of the Company's operations as an investment company and the number of investments held in the portfolio which consists primarily of early-stage companies and their related technologies. As a result, the investment portfolio is directly exposed to the risks associated with companies operating in these industry sectors.

As at June 30, 2020, approximately 99% (2019-96%) of the fair value of the Company's investment portfolio consisted of investments in three companies with the largest single investment comprising 70% (2019-70%) of the total portfolio value.

OUTSTANDING SHARE DATA

As of the date of this MD&A, the Company had the following outstanding share data:

Common shares	83,543,235
Warrants	15,500,000
Finders warrants	1,944,250
Share options	6,106,023

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

Statements in this MD&A – Quarterly Highlights other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, constitute forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, among others, statements pertaining to:

- The price of medical cannabis
- The lack of control over operations of the Company's investment operations;
- The fluctuations in the price of the Company's shares and the share price of the Company's investments;
- The Company's ongoing investment strategy;
- The Company's ability to generate cash flow.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this MD&A – Quarterly Highlights and, other than as required by applicable securities laws, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

ADDITIONAL INFORMATION

Additional information is available on SEDAR at www.sedar.com, or by contacting the Company's corporate office at Suite 810 – 789 West Pender Street, Vancouver, BC, Canada V6C 1H2, or by emailing the Company at alex@resincocp.com.

RISK FACTORS

This section discusses factors relating to the business of Company that should be considered by both existing and potential investors. The information in this section is intended to serve as an overview and should not be considered comprehensive and the Company may face risks and uncertainties not discussed in this section, or not currently known to us, or that we deem to be immaterial. All risks to the Company's business have the potential to influence its operations in a materially adverse manner.

Sector Specific Investment Risks

The Company seeks a high return on investment opportunities on its cannabis pharmaceuticals, mining and natural resource and block chain technology sectors ("Sectors"). Thus, the Company is exposed to investment risks relating to these Sectors which is generally more volatile than the overall market. Investing in these Sectors can be speculative in nature and the value of the Company's investments may be subject to significant fluctuations. Such businesses entail a degree of risk, regardless of the skill and experience of the corporation's management. The assets, earnings and share values of corporations involved in the cannabis pharmaceuticals, natural resource and block chain development, are subject to risks associated with the world prices of various cannabis related products, natural resource and cryptocurrencies, forces of nature, economic cycles, commodity prices, exchange rates, royalty and taxation changes and political events. Government restrictions, such as price regulations, production quotas, royalties and environmental protection, can also be factors.

RISK FACTORS (continued)

Regulatory Risks

The Company's Investment Partners in the cannabis pharmaceutical sector operate in a new industry which is highly regulated, highly competitive and evolving rapidly. As such, new risks may emerge, and management may not be able to predict all such risks or be able to predict how such risks may result in actual results differing from the results contained in any forward-looking statements. The Company's Investment Partners incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional costs for corrective measures, penalties or in restrictions of operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company's Investment Partners and, therefore, on the Company's prospective returns.

The industry is subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The marketability of any product may be affected by numerous factors that are beyond the control of the Company and its Investment Partners and which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce the Company's and its Streaming Partners' earnings and could make future capital investments or the Company's and its Streaming Partners' operations uneconomic. The industry is also subject to numerous legal challenges, which may significantly affect the financial condition of market participants and which cannot be reliably predicted.

Change in Law, Regulations and Guidelines

The Company's Investment Partners are subject to a variety of laws, regulations and guidelines relating to marketing, acquisition, manufacture, management, transportation, storage, sale and disposal of cannabis pharmaceuticals and cannabis pharmaceutical related products but also laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Changes to such laws, regulations and guidelines may cause adverse effects to the Company's investments in the cannabis pharmaceutical sector.

Jurisdictions Outside of Canada

The Company intends to invest into early-stage global cannabis pharma related Company's with operations and business that may be outside of Canada's jurisdiction. There can be no assurance that any market for the Company's Investment Partners products will develop in any such foreign jurisdiction.

The Company may face new or unexpected risks or significantly increase its exposure to one or more existing risk factors, including economic instability, changes in laws and regulations and the effects of competition. These factors may limit the Company's capability to successfully invest in foreign cannabis pharmaceutical entities and may have a material adverse effect on the Company's business, financial condition and results of operations.

Political and Economic Instability

The Company may be affected by possible political or economic instability. The risks include, but are not limited to, terrorism, military repression, extreme fluctuations in currency exchange rates and high rates of inflation. Changes in medicine and agriculture development or investment policies or shifts in political attitude in certain countries may adversely affect the Company's business. Operations may be affected in varying degrees by government regulations with respect to restrictions on production, distribution, price controls, export controls, income taxes, expropriation of property, maintenance of assets, environmental legislation, land use, land claims of local people and water use. The effect of these factors cannot be accurately predicted.

RISK FACTORS (continued)

Limited Operating History

The Company has limited operating history as an investment company, and has had limited success investing in mining, block chain technology and cannabis pharmaceutical sectors. The Company and its business prospects must be viewed against the background of the risks, expenses and problems frequently encountered by companies in the early stages of their development, particularly companies in new and rapidly evolving markets such as the cannabis pharmaceuticals and blockchain market. There is no certainty that the Company will be able to operate profitably.

Additional Requirements for Capital

Substantial additional financing may be required if the Company is to be successful in developing a diversified and material portfolio of investments. No assurances can be given that the Company will be able to raise the additional capital that it may require for its anticipated future development. Any additional equity financing may be dilutive to investors and debt financing, if available, may involve restrictions on financing and operating activities. There is no assurance that additional financing will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations or anticipated investments.

Key Personnel

The Company is dependent upon the continued availability and commitment of its management, whose contributions to immediate and future operations are of significant importance. The loss of any such management could negatively affect the Company's business operations. From time to time, the Company will also need to identify and retain additional skilled management to efficiently operate its business. Recruiting and retaining qualified personnel is critical to the Company's success and there can be no assurance of its ability to attract and retain such personnel. If it is not successful in attracting and training qualified personnel, the Company's ability to execute its business model and growth strategy could be affected, which could have a material and adverse impact on its profitability, results of operations and financial condition.

Lack of Control or significant influence over Companies in which the Company Invests

In certain cases, the Company invests or may invest in securities of companies that the Company does not control or influence. These investments will be subject to the risk that the company in which the investment is made may make business, financial or management decisions with which the Company does not agree or that the majority stakeholders or management of the company may take risks or otherwise act in a manner that does not serve the Company's interests. If any of the foregoing were to occur, the values of investments by the Company could decrease and the Company's financial condition and cash flow could suffer as a result.

Due Diligence

The due diligence process undertaken by the Company in connection with investments that it makes or wishes to make may not reveal all relevant facts in connection with an investment. Before making investments, the Company will conduct due diligence investigations that it deems reasonable and appropriate based on the facts and circumstances applicable to each investment. When conducting due diligence investigations, the Company may be required to evaluate important and complex business, financial, tax, accounting, environmental and legal issues. Outside consultants, legal advisors, accountants and investment banks may be involved in the due diligence process in varying degrees depending on the type of investment. Nevertheless, when conducting due diligence investigations and making an assessment regarding an investment, the Company will rely on resources available, including information provided by the target of the investment and, in some circumstances, third party investigations. The due diligence investigations that are carried out with respect to any investment opportunity may not reveal or highlight all relevant facts that may be necessary or helpful in evaluating such investment opportunity. Moreover, such investigation will not necessarily result in the investment being successful.

Fluctuations in the Value of the Company and the Common Shares

The net asset value of the Company and market value of its common shares will fluctuate with changes in the market value of the Company's investments. Such changes in value may occur as the result of various factors, including general economic and market conditions, the performance of corporations whose securities are part of the Company's investment portfolio and changes in interest rates which may affect the value of interest-bearing securities owned by the Company. There can be no assurance that shareholders will realize any gains from their investment in the Company and may lose their entire investment.